Woodcock to return to CDER director post

Share this article:
Janet Woodcock
Janet Woodcock
FDA deputy commissioner Janet Woodcock will return to the role of permanent director of the Center for Drug Evaluation and Research following a “national search” to fill the slot.

Woodcock had been serving as acting director of CDER after previous director Stephen Galson was appointed Surgeon General last fall. Woodcock has been with the FDA for 21 years and held the title of CDER director from 1994 until 2005. In accepting the permanent director job, Woodcock is also expected to give up her current title as deputy commissioner for scientific and medical programs.
“Dr. Woodcock's exemplary service since October was confirmation of her being ideally suited to lead the center during this crucial period following the passage of the Food and Drug Administration Amendments Act of 2007,” said FDA Commissioner Andrew von Eschenbach in a statement. "The agency is fully committed to implementing the drug safety programs laid out by this Act and meeting the goals set under the Prescription Drug User Fee program, which will help ensure that CDER has the additional resources that are needed to conduct these very complex and comprehensive reviews."

The FDA's CDER division is tasked with overseeing the safety and effectiveness of prescription and over-the-counter drugs used in the US.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...